recent advances in migraine
Post on 11-Feb-2017
1.546 Views
Preview:
TRANSCRIPT
01/05/2023 Department of Pharmacology & Therapeutics 1
Recent Advances: Migraine
Guide: Dr Raakhi Tripathi
JR-2: Dr Anup Petare
01/05/2023 Department of Pharmacology & Therapeutics 2
Recent Advances: Migraine
Guide: Dr Raakhi Tripathi
JR-2: Dr Anup Petare
01/05/2023 Department of Pharmacology & Therapeutics 3
Overview
• Definition• Epidemiology• Types/Classification/Grades• Pathogenesis• Current therapy• Recent advances
01/05/2023 Department of Pharmacology & Therapeutics 4
Migraine is a chronic neurological disorder characterized by recurrent attacks of headache widely variable in intensity, frequency and duration. Attacks are commonly unilateral and are usually associated with anorexia, nausea and vomiting.
Migraine
- World Federation of Neurology
01/05/2023 Department of Pharmacology & Therapeutics 5
MigraineDisabling Primary Headache disorder
Ranked 19th by the WHO among all diseases world-wide causing disability
IHS: migraine constitutes 16% of primary headaches
In India, 15-20% of people suffer from migraine with M:F ratio of 1:2
WHO: Severe migraine can be as disabling as quadriplegia
01/05/2023 Department of Pharmacology & Therapeutics 6
Two major sub-types,
Migraine without aura (common migraine)• Headache with specific features and associated
symptoms
Migraine with aura (classic migraine)• Focal neurological symptoms that usually precede or
sometimes accompany the headache. • Some experience premonitory phase, occurring hours
or days before the headache, and a headache resolution phase
01/05/2023 Department of Pharmacology & Therapeutics 7
01/05/2023 Department of Pharmacology & Therapeutics 8
Grades of Migraine Mild migraine: may be one attack per month throbbing but tolerable headache lasting upto 8 hours which does not incapacitate the individual
Moderate migraine: The throbbing headache more intense, lasts for 6-24 hours, nausea/vomiting and other features are more prominent patient is functionally impaired. One or more attacks occur per month.
Severe migraine: 2-3 or more attacks per month of severe throbbing head ache lasting 12-48 hours, often accompanied by vertigo, vomiting and other symptoms; the subject grossly incapacitated during the attack.
01/05/2023 Department of Pharmacology & Therapeutics 9
Pathogenesis
Vascular theory
Neurogenic
theory
Neurogenic
inflammation
Aura results from intracranial vaso-constriction Headache results from subsequent rebound vasodilatation
Cortical spreading depression of the electrical activity followed by vascular pheno mena
Triggered by Trigeminal sensory system mediated by 5-HT, neurokinin, substance P, calcitonin gene related peptide (CGRP), nitric oxide, etc.
01/05/2023 Department of Pharmacology & Therapeutics 10
Neurovascular Theory
01/05/2023 Department of Pharmacology & Therapeutics 11
Signaling cascade
Current therapeutic option..
Acute treatment
Preventive
treatmentBehavioural treatment
To reduce pain and duration of attack
To reduce frequency of attacks and
disability
Identification of triggers Meditation Psychotherapy
Acute/ Abortive therapy
Non-specific treatment: NSAID’sSpecific treatment: Ergot alkaloids 5-HT receptor agonist (Triptans)
Acute therapy: TriptansSelective 5-HT 1B/1D agonist Sumatriptan Almotriptan Eletriptan Frovatriptan Naratriptan Rizatriptan Zolmitriptan
Similar efficacyDiffering
Pharmacokinetic profile
Acute / Abortive therapyFailed analgesics or NSAIDsOral Sumatriptan 50 mg or 100 mg, Rizatriptan 10mg Almotriptan 12.5 mg, Eletriptan 40 mg, Zolmitriptan 2.5 mg
For slower effect or better tolerability: Oral Naratriptan 2.5 mg, Frovatriptan 2.5 mg
Infrequent headache:Ergotamine 1-2 mg oral, Dihydroergotamine nasal spray 2 mg
Headache recurrenceErgotamine 2 mg (perhaps most effective taken rectally, usually with caffeine)Oral Naratriptan 2.5 mg and Eletriptan 80 mg
Early nausea or difficulties taking tabletsSumatriptan 20 mg nasal spray, Zolmitriptan 5 mg nasal spray, Rizatriptan 10 mg dissolvable wafer, zolmitriptan 2.5 mg dispersible tablet ± Anti-emetics
Early vomitingSumatriptan 25 mg suppository, Sumatriptan 6 mg subcutaneous injection ± Anti-emetics
Rapidly developing symptomsSumatriptan 6 mg subcutaneous injection,Dihydroergotamine 1 mg intramuscular injection
Acute / Abortive therapy
Contraindications to Triptans
Coronary artery disease Hypertension Peripheral vascular disease Hemiplegic or Basilar migraine Avoid in those on Ergots, SSRI and TCA Pregnancy and Lactation Should not be used for more than 2 days a week
to decrease the possibility of rebound headache
Preventive therapy
Beta- blockers Propranolol Metoprolol Timolol
Calcium channel blockers Flunarizine Verapamil
Tricyclic antidepressants Amitryptiline Nortryptiline
Anti-epileptics/ Neurostabilizers Topiramate Divalproex sodium Gabapentin
Serotonin antagonists Pizotifen Methysergide
Serotonergic agents Dihydroergotamine
Recent advances
New FDA approvals
New uses of existing drugs
Drugs in pipeline
New devices
01/05/2023 Department of Pharmacology & Therapeutics 20
Recent Advances: In acute Treatment
Brandes JL, Kudrow D, Stark SR, O'Carroll CP, Adelman JU, O'Donnell FJ, Alexander WJ, Spruill SE, Barrett PS, Lener SE. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007;297:1443–54. doi: 10.1001/jama.297.13.1443.
01/05/2023 Department of Pharmacology & Therapeutics 21
Reduction in migraine frequency in patients with chronic migraine with analgesic overuse.
Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia. 2003;23:820–4. doi: 10.1046/j.1468 2982.2003.00592.x.Silberstein SD, et L Topiramate Chronic Migraine Study Group Efficacy and safety of topiramate for the treatment of chronic migraline: a randomised, double blind, placebo controlled trial. Headache.2007;47:170–80. doi: 10.1111/j.1526 4610.2006.00684.x. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, TOPMAT MIG 201(TOP CHROME) Study Group Topiramate reduces headache days in chronic migraine: a randomised, double blind, placebo controlled study. Cephalalgia. 2007;27:814–23. doi: 10.1111/j.1468 2982.2007.01326.x.
01/05/2023 Department of Pharmacology & Therapeutics 22
New FDA approvals
01/05/2023 Department of Pharmacology & Therapeutics 23
TOPAMAX
• March 28, 2014: 1st FDA approval for prophylaxis of migraine headaches in adolescents ages 12 to 17 (100mg)
• ADR: paresthesia, upper respiratory infection, anorexia, abdominal pain
01/05/2023 Department of Pharmacology & Therapeutics 24
Treximet
• Treximet (Sumatriptan/Naproxen Sodium) Formerly Known as TREXIMA,
• May 2012: Menstrual Migraine in Women With Dysmenorrhea Phase 3 study was completed
https://clinicaltrials.gov/ct2/show/NCT00329459?term=Imitrex+menstrual+migraine&rank=1
01/05/2023 Department of Pharmacology & Therapeutics 25
Zomig (Zolmitriptan)
• October 2008: USFDA approved Zomig (zolmitriptan) Nasal Spray
• Jan 2015: Treatment of Acute Migraine Headache in Adolescents (TEENZ) Phase 4 study was completed
01/05/2023 Department of Pharmacology & Therapeutics 26
BOTOX® (OnabotulinumtoxinA)
• 15 Oct 2010 USFDA approved Botox inj : Prevent headaches in adult patients with chronic
migraine. every 12 weeks as multiple injections around the head and neck
• ADR: neck pain and headache.
• Boxed warning: Botulinum toxin may spread from the area of injection to other areas of the body, causing symptoms similar to those of botulism
01/05/2023 Department of Pharmacology & Therapeutics 27
Transdermal patch: Sumatriptan
January 2013, FDA approved: acute medication sumatriptan delivery by new mechanism (transdermal patch)
ADR: Painful sensation at the patch application site, reddening
01/05/2023 Department of Pharmacology & Therapeutics 28
• Otopoint-needle implant can effectively relieve headache in migraine patients
• Upregulate plasma 5-HT level.
http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/654/CN-00778654/frame.html accessed on 3.4.2015.
Acupuncture:
New uses of existing drugs
Dexamethasone addition to standard acute therapy
Proposed to prevent recurrence of migraine through its prevention of neurogenic inflammation
7 Randomized clinical trials (n = 742)
Dexamethasone vs placebo (both + standard therapy): Dexa group was less likely to experience recurrent headache within 24 to 72 hours
Conclusion: Dexamethasone appears to be safe and modestly effective addition to standard migraine abortive therapy for the prevention of migraine recurrenceGiuliano C, Smalligan RD, Mitchon G, Chua M. Role of dexamethasone in the prevention of migraine recurrence in the acute care setting: a review. Postgrad Med. 2012
May;124(3): 110-5
Carvedilol
Additional alpha-1 blocking and antioxidant properties
A very favourable adverse event profile A prospective, open-label trial in 76 patients with
doses titrated from 3.125 mg/day to 6.25 mg twice daily over 2 weeks revealed,
50% reduction in monthly migraine attack frequency at the third month of treatment in 59% patients,
But, 26% patients withdrew due to lack of efficacy or as a result of adverse eventsBigal ME, Krymchantowski AV. Emerging Drugs for Migraine Prophylaxis and Treatment. Medscape General Medicine. 2006;8(2):31.
Tiagabine (TGB) Inhibits the neuronal and glial reuptake of GABA and
therefore enhances GABA-mediated inhibition Open-label study in 41 patients with refractory
migraine using a mean dose of 10 mg/day TGB revealed,
5 patients experienced a remission of their migraine attacks
33 patients had at least a 50% reduction in their attacks
Side effects reported were dizziness, asthenia, tremor and abdominal pain
Safety alert issued in 2005: Risk of new onset seizures and status epilepticus in patients without a history of epilepsy
Levetiracetam Promising drug for the treatment of transformed
migraine Open label trial in 36 transformed migraine patients
with 1000 mg/day of LCT revealed significant reduction in headache frequency at 1 month and 3 months
Efficacy and safety evaluated in 30 patients ( aged 6 – 19 years) with paediatric migraine with 125 – 250 mg BD revealed,
At least 50% reduction in headache frequency and severity in 17 patients with improved quality of life
Used off-label for migraine prophylaxis
Brighina F, Palermo A, Aloisio A, Francolini M, Giglia G, Fierro B. Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study. Clin Neuropharmacol. 2006 Nov-Dec;29(6):338-42
Miller GS. Efficacy and safety of levetiracetam in pediatric migraine. Headache. 2004 Mar;44(3):238-43
Zonisamide
Unique combination of pharmacologic actions: Blocks voltage-dependent sodium and T-type
calcium channels Reduces glutamate-mediated excitatory
neurotransmission Inhibits excessive nitric oxide (NO) production,
scavenging hydroxyl and NO radicals Inhibits carbonic anhydraseAll of these mechanisms may play a role in headache and pain modulation possibly via neuronal stabilization
2 open-label trials:
One in 33 patients and second in 34 patients with
refractory migraine with 100 mg/day Zonisamide
showed,
Significant reduction in frequency and severity of
migraine
Side effects reported included paraesthesia,
fatigue, anxiety, and weight lossBermejo PE, Dorado R. Zonisamide for migraine prophylaxis in patients refractory to topiramate. Clin Neuropharmacol. 2009 Mar-Apr;32(2):103-6
Quetiapine
Atypical antipsychotic drug with a high affinity for D4 receptors
Also possesses, High affinity for 5-HT2 receptors Partial agonistic activity at 5-HT1A receptors Blocking activity at alpha1-adrenergic receptors In an open label pilot study in 34 pts with
refractory migraine, 75.9% presented > 50% headache reduction
Potential for migraine prophylaxis
Krymchantowski AV, Jevoux C. Quetiapine for the prevention of migraine refractory to the combination of atenolol + nortriptyline + flunarizine: an open pilot study. Arq Neuropsiquiatr. 2008 Sep;66(3B):615-8.
Tizanidine hydrochloride Alpha-2-adrenergic presynaptic agonist that
inhibits the release of norepinephrine in the brainstem and spinal cord
An open study of 220 patients demonstrated efficacy in chronic migraine
Evidence supports tizanidine as an effective prophylactic adjunct for chronic daily headache
Also, possible importance of an alpha2-adrenergic mechanism underlying the pathophysiology of migraine is suggested
Saper JR, Lake AE 3rd, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002 Jun;42(6):470-82.
Petasites/Butterbur
Extract from the plant Petasites hypridus (butterbur) Inhibits peptide-leukotriene biosynthesis, possibly
through calcium channel regulation efficacy in migraine prevention was studied in 2 trials, A small RCT reported: low dose of petasites, 50 mg
twice daily, significantly reduced the number of migraine attacks per month and the number of migraine days per month
A larger RCT over 5 month by Lipton and colleagues reported:
4-month mean attack count reduced by 48% in patients treated with petasites 75 mg twice daily, by 34% with petasites 50 mg twice daily
01/05/2023 Department of Pharmacology & Therapeutics 38
Holland PR, Akerman S, Andreou AP, Karsan N, Wemmie JA, Goadsby PJ. Acid-sensing ion channel 1: a novel therapeutic target for migraine with aura. Ann Neurol. 2012 Oct;72(4):559-63. doi: 10.1002/ana.23653. PubMed PMID: 23109150.
Acid-sensing ion channel 1
• Novel therapeutic target for migraine with aura.
• Amiloride: Shown to block cortical spreading depression via this mechanism
01/05/2023 Department of Pharmacology & Therapeutics 39
01/05/2023 Department of Pharmacology & Therapeutics 40
Drugs in pipeline
01/05/2023 Department of Pharmacology & Therapeutics 41
Phase 3: Completed
TARGET:A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of a Single 20 mg Dose of Sumatriptan Powder Delivered Intra-nasally with the Bi-Directional Device in Adults With Acute Migraine With or Without AuraHead-to-Head Comparison Trial: COMPASS: Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-Directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without AuraPG Djupesland, P Dočekal, the Czech Migraine Investigators Group Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study Cephalalgia August 2010 vol. 30 no. 8 933-942
01/05/2023 Department of Pharmacology & Therapeutics 42
NXN-188
• 20 July 2014 trial NXN 188 for the Treatment of Migraine With Aura completed its Phase 2
• Immediate release oral product
• Novel mechanism, selective inhibition of neuronal Nitric Oxide Synthase (nNOS), as well as 5-HT1B/1D activation
01/05/2023 Department of Pharmacology & Therapeutics 43
Levadex (Dihydroergotamine)
• Multi-center trial, FREEDOM-301, consisted of a randomized, double blind, placebo-controlled
• 16 April 2013 USFDA issued Complete Response Letter on NDA of Levadex raising concern over manufacturing process for the final filled canisters.
01/05/2023 Department of Pharmacology & Therapeutics 44
• Glutamate receptors antagonist
• In 2007 Phase 2 was completed
https://clinicaltrials.gov/ct2/show/NCT00567086?term=tezampanel&rank=1
Tezampanel(NGX424MIG2001)
01/05/2023 Department of Pharmacology & Therapeutics 45
Telcagepant (MK-0974)
• In 2010 merck terminated it study with Telcagepant
(0974-049) • Terminated: Identification of two patients with
significant elevations in serum transaminases
• 27 Jan 2015: Phase 3 study of Telcagepant (MK-0974-011) in Participants With Moderate to Severe Acute Migraine With or Without Aura
https://clinicaltrials.gov/ct2/show/NCT00442936?term=telcagepant&rank=1
• Antagonist of the receptor for CGRP
01/05/2023 Department of Pharmacology & Therapeutics 46
Edvinsson L. CGRP receptor antagonism in migraine treatment. Lancet. 2008;372:2089–90. doi:10.1016/S0140 6736(08)61710 9.
ADX10059
01/05/2023 Department of Pharmacology & Therapeutics 47
New devices
01/05/2023 Department of Pharmacology & Therapeutics 48
• 13 December 2013: FDA allows marketing of first device to relieve migraine headache pain (Cerena)
• Device delivers Pulse transcranial magnetic stimulation at the onset of headache or aura
• Disrupts cortical spreading depressionwww.accessdata.fda.gov/cdrh_docs/pdf13/den130022.pdf
Cerena
01/05/2023 Department of Pharmacology & Therapeutics 49
Cefaly
http://www.accessdata.fda.gov/cdrh_docs/pdf12/k122566.pdf
• 11 March 2014: USFDA approved device for preventing migraine.
• Transcutaneous Electrical Nerve Stimulator to Treat Headache
• Warnings: Indicated for use by adults and should only be used for 20 minutes/day,
• ADR: Tingling or massaging sensation where electrode applied.
01/05/2023 Department of Pharmacology & Therapeutics 50
Conclusion• <60% migraine patients respond & tolerate preventatives1
• Need for better options for the symptomatic and preventative treatment of migraine
• future seems bright as understanding of the disease improving newer and safer treatment are rising.
1: Pascual J. Recent advances in the pharmacological management of migraine. F1000 Med Rep. 2009 May 8;1. pii: 39. doi: 10.3410/M1-39. PubMed PMID: 20948742; PubMed Central PMCID: PMC2924709.
top related